ArticleImmunotherapy2020
Hematopoietic stem cell transplantation and chimeric antigen receptor T cell for relapsed or refractory diffuse large B-cell lymphoma.
Abstract read
In one paragraph
Article in Immunotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effectiveness and safety of CD22 and CD19 dual-targeting chimeric antigen receptor T-cell therapy in patients with relapsed or refractory B-cell malignancies: A meta-analysis.Cancer medicine · 2023Pooled it
- Efficacy and safety of chimeric antigen receptor T-cell therapy in relapsed/refractory large B-cell lymphoma: a systematic review and meta-analysis.Therapeutic advances in hematology · 2026Article
- Bridging transplantation and immunotherapy: Clinical promise of autologous stem cell transplantation with chimeric antigen receptor T-cell therapy.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Clinical outcomes of chimeric antigen receptor T-cell therapy following autologous hematopoietic stem cell transplantation in 38 patients with refractory/relapsed primary or secondary central nervous system lymphoma.Cancer immunology, immunotherapy : CII · 2024Article
- Article
- Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma.Journal for immunotherapy of cancer · 2024Article
- Article
- Progress and prospect of ASCT combined with CAR-T therapy in the treatment of multiple myeloma.Therapeutic advances in hematology · 2024Review
- The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma.Experimental hematology & oncology · 2023Review
- Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience.Haematologica · 2023Review
- CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies.Frontiers in immunology · 2023Review
- CD19 chimeric antigen receptor T-cell therapy following autologous stem cell transplantation against relapsed or refractory Burkitt lymphoma/leukemia: A case report and literature review.Frontiers in oncology · 2022Article
- Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma.Frontiers in immunology · 2022Article
- The risk factors and early predictive model of hematotoxicity after CD19 chimeric antigen receptor T cell therapy.Frontiers in oncology · 2022Article
- The Autologous Hematopoietic Stem Cells Transplantation Combination-Based Chimeric Antigen Receptor T-Cell Therapy Improves Outcomes of Relapsed/Refractory Central Nervous System B-Cell Lymphoma.Journal of oncology · 2022Article
- Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies.Frontiers in immunology · 2022Review
- Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma.Blood cancer journal · 2021Article
- Efficacy and Safety of Innovative Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review.Innovations in pharmacy · 2021Article
- Autologous stem cell transplantation meets CAR-T therapy: A synergistic strategy for B-cell lymphoma.Cell transplantationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Tao WangDepartment of Hematology, Institute of Hematology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.ORCID 0000-0002-1789-9767
Lei GaoDepartment of Hematology, Institute of Hematology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
Yujie WangDepartment of Hematology, Institute of Hematology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
Wenjun ZhuCenter for Cell Engineering, Clinical Center, National Institutes of Health, Bethesda, MD, USA.
Lili XuDepartment of Hematology, Institute of Hematology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
Yang WangDepartment of Hematology, Institute of Hematology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
Wenqin YueDepartment of Hematology, Institute of Hematology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
Gusheng TangDepartment of Hematology, Institute of Hematology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
Li ChenDepartment of Hematology, Institute of Hematology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
Jie ChenDepartment of Hematology, Institute of Hematology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
Weiping ZhangDepartment of Hematology, Institute of Hematology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
Xuejun YuHuaDao Biopharma (Shanghai) Limited Corporation, Shanghai 201210, China.
Dongge FengHuaDao Biopharma (Shanghai) Limited Corporation, Shanghai 201210, China.
Jianmin YangDepartment of Hematology, Institute of Hematology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedDisease-Free SurvivalFemaleHematopoietic Stem Cell TransplantationHumansImmunotherapyLymphoma, Large B-Cell, DiffuseMaleMiddle AgedNeoplasm Recurrence, LocalPilot ProjectsReceptors, Antigen, T-CellReceptors, Chimeric AntigenTreatment OutcomeYoung AdultReceptors, Antigen, T-CellReceptors, Chimeric Antigenautologous hematopoietic stem cell transplantationchimeric antigen receptor T-cell therapydiffuse large B-cell lymphomarelapsed or refractorysafety
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.